Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation  by Gilani, Sadaf J. et al.
Arabian Journal of Chemistry (2016) 9, S1523–S1531King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEBenzothiazole incorporated thiazolidin-4-ones
and azetidin-2-ones derivatives: Synthesis
and in vitro antimicrobial evaluation* Corresponding author. Tel.: +91 9891128162; fax: +91 0120
2675091.
E-mail address: gilanisadaf@gmail.com (S.J. Gilani).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2012.04.004
1878-5352 ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Sadaf J. Gilani a,*, K. Nagarajan a, Surya P. Dixit a,
M. Taleuzzaman a, Suroor A. Khan ba Department of Pharmaceutical Chemistry, KIET School of Pharmacy, Ghaziabad 201206, UP, India
b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), NewDelhi 110062, IndiaReceived 17 January 2012; accepted 2 April 2012
Available online 11 April 2012KEYWORDS
N-(6-chlorobenzo[d]thiazol-
2-yl)hydrazine carboxamide;
Benzothiazole;
Thiazolidin-4-ones;
Azetidin-2-ones;
Antimicrobial activityAbstract In this study, a series of novel thiazolidin-4-ones (5a–g) and azetidin-2-ones (6a–g) were
synthesized from N-(6-chlorobenzo[d]thiazol-2-yl)hydrazine carboxamide derivatives of the benzo-
thiazole class. Antimicrobial properties of the title compound derivatives were investigated against
one Gram (+) bacteria (Staphylococcus aureus), three Gram () bacteria (Escherichia coli, Pseudo-
monas aeruginosa, Klebsiella pneumoniae) and ﬁve fungi (Candida albicans, Aspergillus niger, Asper-
gillus ﬂavus, Monascus purpureus and Penicillium citrinum) using serial plate dilution method. The
investigation of antibacterial and antifungal screening data revealed that all the tested compounds
showed moderate to good inhibition at 12.5–200 lg/mL in DMSO. It has been observed that azeti-
din-2-ones derivatives are found to be more active than thiazolidin-4-ones derivatives against all
pathogenic bacterial and fungal strains.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Antimicrobial agents are among the most commonly used and
misused of all drugs (Nogrady and Weaver, 2005). They reduce
or completely block the growth and multiplication of bacteria.
This has made them unique for the control of deadly infectious
diseases caused by a variety of pathogens (Gilani et al.,
2011a,b). Although deaths from bacterial and fungal infections
have dropped in the developed world, these are still major
causes of death in the developing world. The inevitable conse-
quence of the widespread use of antimicrobial agents has been
the emergence of antibiotic-resistant pathogens, fueling an
ever-increasing need for new drugs. In the design of new
S1524 S.J. Gilani et al.compounds, development of hybrid molecules through the
combination of different pharmacophores in one structure
may lead to compounds with increased antimicrobial activity.
In addition, the 2-azetdinone ring system, a common struc-
tural feature of a number of wide spectrum b-lactam antibiot-
ics, including penicillins, cephalosporins, carbapenems,
nocardicins and monobactams, have been widely used as che-
motherapeutic agents to treat bacterial infections and micro-
bial diseases. The azetidin-2-one derivatives have been
reported to possess a wide range of biological activities like
antibacterial (Patel and Patel, 2011), antifungal (Halve et al.,
2007), anti-inﬂammatory (Gurupadayya et al., 2008), analgesic
(Ishwar Bhat et al., 2003), anticonvulsant (Gilani et al., 2009),
anticancer (Veinberg and Vorona, 2004), and antitubercular
(Kagthara et al., 2000). Similarly, thiazolidin-4-ones are a class
of heterocycles which have attracted signiﬁcant interest in
medicinal chemistry and they have a wide range of pharmaceu-
tical and biological activities including antimicrobial (Mohan
and Kumar, 2003), anti-inﬂammatory (Vigorita et al., 2003),
analgesic (Kumar et al., 2007), antitubercular (Kucukguzel
et al., 2006) and antidiabetic (Pattan et al., 2005). Biocidal
activities of Schiff bases have also been well established. These
have been attributed to the toxophoric C‚N linkage in them.
Schiff base acquired broad spectrum biological activities like
antibacterial (Iqbal et al., 2007), antifungal (Mishra et al.,
2005), antitubercular (Lourenco et al., 2007) and anticonvul-
sant (Ragavendran et al., 2007).
The rationale for the study includes the designing of the
derivatives having some common structural features that are
important for the compound to exhibit an antimicrobial activ-
ity that includes the following:
1. A lipohilic bicyclic aromatic ring system.
2. Another bulky lipophilic group (e.g. phenyl, tert butyl) as a
side chain.
3. Two lipophilic domains linked by a spacer of appropriate
length with polar center at deﬁned position, for example,
naftiﬁne, butenaﬁne, terbinaﬁne, debacarb, penicillins and
cephalosporins (Nussbaumer et al., 1994, 1995).
In view of the above mentioned facts and in continuation of
our interest in the synthesis of heterocycles containing benzo-
thiazole moiety, to identify new candidates that may be of
value in designing new, potent, selective and less toxic antimi-
crobial agents, we report herein the synthesis and antimicrobial
evaluation of some novel structural hybrids incorporating both
the benzothiazole moiety with thiazolidin-4-one and azetidin-2-
one ring systems through different linkages. This combination
was suggested in an attempt to investigate the inﬂuence of such
hybridization and structural variation on the anticipated anti-
microbial activity, hoping to add some synergistic biological
signiﬁcance to the target molecules. The substitution pattern
of thiazolidin-4-one (5a–g) and azetidin-2-one (6a–g) rings
was carefully selected so as to confer different electronic envi-
ronment to the molecules.
2. Experimental
2.1. General
All the solvents were of AR grade and were obtained from
Merck, CDH and S.D. Fine chemicals. Melting points weredetermined in open capillary tubes and are uncorrected. All
the compounds were subjected to elemental analysis (CHN)
and the measured values agreed within ±0.4% with the calcu-
lated ones. Thin layer chromatography was performed on silica
gel G (Merck). The spots were developed in an iodine chamber
and visualized with an ultraviolet lamp. The solvent systems
used were benzene–acetone (8:2, v/v) and toluene–ethyl ace-
tate–formic acid (5:4:1, v/v). Ashless Whatman No. 1 ﬁlter pa-
per was used for vacuum ﬁltration. The spots were developed in
an iodine chamber and visualized under an ultraviolet (UV)
lamp. The IR spectra were recorded in KBr pellets on a
(BIO-RAD FTS 135) WIN-IR spectrophotometer. The FAB
mass spectra of all the compounds were recorded on a JEOL
SX102/ /DA-600 mass spectrometer using argon/xenon (6 kV,
10 mA) as the FAB gas. 1H NMR spectra (d, ppm) were re-
corded in DMSO-d6 solutions on a Varian-Mercury 300 MHz
spectrometer using tetramethylsilane as the internal reference.
13C NMR spectra were recorded in DMSO-d6 solutions on a
Bruker Avance II 400 spectrometer at 400 MHz using tetra-
methylsilane as the internal reference. 2-Amino-6-chloro-ben-
zothiazole 1 was synthesized by the literature procedure
(Gilani et al., 2011b).2.2. Synthesis of 1-(6-chlorobenzo[d]thiazol-2-yl)urea (2)
To the solution of sodium cyanate in minimum quantity
of water, glacial acetic acid (5 mL) was added. This solution
was heated with 2-amino-6-chloro-benzothiazole 1 (0.01 mol)
in alcohol till the contents of the mixture became turbid and
the volume remained half of the original volume. The contents
were added to ice cool water. The solid obtained was ﬁltered
off, dried and recrystallised from a suitable solvent.
IR (KBr) kmax (cm
1): 3310 (NH), 1628 (C‚O), 1560
(C‚N), 830 (C–Cl), 645 (C–S–C benzothiazole); 1H NMR
(300 MHz, DMSO-d6) d ppm: 9.14 (s, 1H, NHC‚O), 6.68–
6.70 (m, 3H, Ar-H, J= 6 Hz), 6.34 (s, 2H, NH2).2.3. Synthesis of N-(6-chlorobenzo[d]thiazol-2-yl)hydrazine
carboxamide (3)
To the warm hydrazine hydrate solution of compound 2 in
alcohol, conc. NaOH was added and reﬂuxed for 6 h. The
reaction mixture was poured into crushed ice and solid ob-
tained was ﬁltered off and dried. The solid collected out was
recrystallized from a suitable solvent to get the compound
N-(6-chlorobenzo[d]thiazol-2-yl)hydrazine carboxamide.
IR (KBr) kmax (cm
1): 3300 (NH), 1660 (C‚O), 1588
(C‚N), 817 (C–Cl), 657 (C–S–C benzothiazole); 1H NMR
(300 MHz, DMSO-d6) d ppm: 9.12 (s, 1H, NHC‚O), 7.28
(s, 1H, NHNH2), 7.70–7.74 (m, 3H, Ar-H, J= 12 Hz).2.4. Synthesis of 2-Substituted benzylidene-N-(6-
chlorobenzo[d]thiazol-2-yl)hydrazinecarboxamide (4a–g)
To an equimolar methanolic solution of N-(6-chloro-
benzo[d]thiazol-2-yl)hydrazine carboxamide (3) (0.1 mol) and
substituted benzaldehyde (0.1 mol), a few drops of glacial ace-
tic acid were added. The mixture was then reﬂuxed on a water
bath for 5–6 h. It was then allowed to cool, poured onto
crushed ice and recrystallised from methanol.
Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis S15252.4.1. 2-Benzylidene-N-(6-chlorobenzo[d]thiazol-2-yl)
hydrazinecarboxamide (4a)
IR (KBr) kmax (cm
1): 3318 (NH), 1668 (C‚O), 1588 (C‚N),
827 (C–Cl), 663 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.12 (s, 1H, NHC‚O), 7.90 (s, 1H,
N‚CH), 7.77–7.781 (m, 8H, Ar-H, J= 12 Hz), 6.10 (s, IH,
NH); MS [EI] m/z 330 [M+], 331 [M++1], 332 [M++2].
2.4.2. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(2-chlorobenzyl
idene)hydrazinecarboxamide (4b)
IR (KBr) kmax (cm
1): 3314 (NH), 1672 (C‚O), 1582 (C‚N),
811 (C–Cl), 649 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.10 (s, 1H, NHC‚O), 7.92 (s, 1H,
N‚CH), 7.73–7.77 (m, 7H, Ar-H, J= 12 Hz), 6.14 (s, IH,
NH); MS [EI] m/z 365 [M+], 364 [M+1].
2.4.3. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(2,4-
dichlorobenzylidene)hydrazinecarboxamide (4c)
IR (KBr) kmax (cm
1): 3320 (NH), 1662 (C‚O), 1587 (C‚N),
818 (C–Cl), 654 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.11 (s, 1H, NHC‚O), 7.94 (s, 1H,
N‚CH), 7.79–7.83 (m, 6H, Ar-H, J= 12 Hz), 6.12 (s, IH,
NH); MS [EI] m/z 401 [M++2]. 399 [M+], 397 [M+2].
2.4.4. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(2-methylbenzy
lidene)hydrazinecarboxamide (4d)
IR (KBr) kmax (cm
1): 3311 (NH), 1669 (C‚O), 1580 (C‚N),
819 (C–Cl), 640 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.09 (s, 1H, NHC‚O), 7.97 (s, 1H,
N‚CH), 7.72–7.76 (m, 7H, Ar-H, J= 12 Hz), 6.13 (s, IH,
NH); MS [EI] m/z 346 [M++2], 345 [M++1], 344 [M+].
2.4.5. 2-[{2-(6-Chlorobenzo[d]thiazol-2-
ylcarbamoyl)hydrazono}methyl]phenyl acetate (4e)
IR (KBr) kmax (cm
1): 3319 (NH), 1664 (C‚O), 1589 (C‚N),
822 (C–Cl), 644 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.17 (s, 1H, NHC‚O), 7.91 (s, 1H,
N‚CH), 7.75–7.79 (m, 7H, Ar-H, J= 12 Hz), 6.16 (s, IH,
NH); MS [EI] m/z 389 [M++1], 388 [M+], 390 [M++2].
2.4.6. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(4-methoxybenzy
lidene)hydrazinecarboxamide (4f)
IR (KBr) kmax (cm
1): 3317 (NH), 1662 (C‚O), 1586 (C‚N),
816 (C–Cl), 654 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.07 (s, 1H, NHC‚O), 7.96 (s, 1H,
N‚CH), 7.77–7.81 (m, 7H, Ar-H, J= 12 Hz), 6.18 (s, IH,
NH); MS [EI] m/z 362 [M++2], 361 [M++1], 360 [M+].
2.4.7. N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(4-
nitrobenzylidene)hydrazinecarboxamide (4g)
IR (KBr) kmax (cm
1): 3323 (NH), 1674 (C‚O), 1591 (C‚N),
822 (C–Cl), 651 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 9.17 (s, 1H, NHC‚O), 7.98 (s, 1H,
N‚CH), 7.78–7.82 (m, 7H, Ar-H, J= 12 Hz), 6.20 (s, IH,
NH); MS [EI] m/z 377 [M++2], 376 [M++1], 375 [M+].
2.5. Synthesis of 1-(6-chlorobenzo[d]thiazol-2-yl)-3-(4-oxo-2-
substituted phenylthiazolidin-3-yl)urea (5a–g)
A mixture of 4 (0.01 mol) and thioglycollic acid (0.01 mol) was
heated on an oil-bath at 120–125 C for 12 h. The reaction
mixture was cooled and treated with 10% sodium bicarbonatesolution. The product was isolated and recrystallised from
methanol–dioxane (4:1).
2.5.1. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(4-oxo-2-phenylthia
zolidin-3-yl)urea (5a)
IR (KBr) kmax (cm
1): 3216 (NH), 3126 (C–H aromatic), 1726
(C‚O thiazolidinone), 1664 (C‚O), 1538 (C‚C aromatic),
1440 (C–N benzothiazole), 830 (C–Cl), 692 (C–S–C thiazolid-
inone), 614 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 11.85 (s, 1H, CONH), 8.05 (s, 1H, NH),
7.65–7.79 (m, 8H, Ar-H), 2.48 (s, 2H, CH2 thiazolidinone);
13C NMR (400 MHz, DMSO-d6) d ppm: 174.5, 168.8, 153.8,
151.3, 139.2, 132.3, 129.8, 128.6, 127.1, 126.9, 125.8, 121.2,
118.3, 63.8, 35.2 (CH2 thiazolidinone); MS [EI] m/z 406
[M++2], 405 [M++1], 404 [M+].
2.5.2. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(2-(2-chloro
phenyl)-4-oxothiazolidin-3-yl)urea (5b)
IR (KBr) kmax (cm
1): 3211 (NH), 3120 (C–H aromatic), 1721
(C‚O thiazolidinone), 1668 (C‚O), 1542 (C‚C aromatic),
1438 (C–N benzothiazole), 836 (C–Cl), 696 (C–S–C thiazolid-
inone), 620 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 11.83 (s, 1H, CONH), 8.03 (s, 1H, NH),
7.51–7.71 (m,7H, Ar-H), 2.42 (s,2H, CH2 thiazolidinone);
13C NMR (400 MHz, DMSO-d6) d ppm: 174.5, 168.8, 153.8,
151.3, 134.0, 132.3, 130.1, 129.8, 128.7, 128.5, 126.7, 125.8,
121.2, 118.3, 102.5, 58.7, 35.2 (CH2 thiazolidinone); MS [EI]
m/z 441 [M++2], 439 [M+], 438 [M+1], 437 [M+2].
2.5.3. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(2-(2,4-dichloro
phenyl)-4-oxothiazolidin-3-yl)urea (5c)
IR (KBr) kmax (cm
1): 3214 (NH), 3112 (C–H aromatic), 1730
(C‚O thiazolidinone), 1661 (C‚O), 1536 (C‚C aromatic),
1430 (C–N benzothiazole), 838 (C–Cl), 681 (C–S–C thiazolid-
inone), 612 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 11.81 (s, 1H, CONH), 8.01 (s, 1H, NH),
7.59–7.76 (m, 6H, Ar-H), 2.46 (s, 2H, CH2 thiazolidinone);
13C NMR (400 MHz, DMSO-d6) d ppm: 174.5, 168.8, 153.8,
151.3, 135.4, 134.1, 132.3, 131.5, 130.3, 129.8, 126.8, 125.8,
121.2, 118.3, 100.6, 58.7, 35.2 (CH2 thiazolidinone); MS [EI]
m/z 475 [M++2], 473 [M+], 471 [M+-2].
2.5.4. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(4-oxo-2-o-tolylthi
azolidin-3-yl)urea (5d)
IR (KBr) kmax (cm
1): 3217 (NH), 3119 (C–H aromatic), 1737
(C‚O thiazolidinone), 1667 (C‚O), 1531 (C‚C aromatic),
1427 (C–N benzothiazole), 842 (C–Cl), 691 (C–S–C thiazolid-
inone), 618 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 11.79 (s, 1H,CONH), 8.07 (s, 1H, NH),
7.62–7.71 (m, 6H, Ar-H), 2.44 (s, 2H, CH2 thiazolidinone),
2.34 (s,3H, CH3);
13C NMR (400 MHz, DMSO-d6) d ppm:
174.5, 168.8, 153.8, 151.3, 139.0, 136.5, 132.3, 130.3, 129.8,
128.6, 127.0, 125.8, 125.6, 121.2, 118.3, 61.3, 35.2 (CH2 thiazo-
lidinone), 18.4; MS [EI] m/z 420 [M++2], 419 [M++1], 418
[M+].
2.5.5. 2-(3-(3-(6-Chlorobenzo[d]thiazol-2-yl)ureido)-4-oxo
thiazolidin-2-yl)phenyl acetate (5e)
IR (KBr) kmax (cm
1): 3225 (NH), 3122 (C–H aromatic), 1724
(C‚O thiazolidinone), 1674 (C‚O), 1540 (C‚C aromatic),
1436 (C–N benzothiazole), 844 (C–Cl), 687 (C–S–C thiazolid-
inone), 622 (C–S–C benzothiazole); 1H NMR (300 MHz,
S1526 S.J. Gilani et al.DMSO-d6) d ppm: 11.81 (s, 1H, CONH), 8.00 (s, 1H, NH),
7.62–7.69 (m,7H, Ar-H), 2.60(s,3H, OCOCH3), 2.51 (s, 2H,
CH2 thiazolidinone), 2.31 (s,3H, CH3);
13C NMR (400 MHz,
DMSO-d6) d ppm: 174.5, 169.0, 168.8, 153.8, 151.3, 150.0,
132.3, 129.8, 127.5, 127.0, 125.8, 125.4, 123.8, 121.5, 121.2,
118.3, 57.8, 35.2 (CH2 thiazolidinone), 20.3; MS [EI] m/z 464
[M++2], 463 [M++1], 462 [M+].
2.5.6. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(2-(2-methoxyp
henyl)-4-oxothiazolidin-3-yl)urea (5f)
IR (KBr) kmax (cm
1): 3230 (NH), 3127 (C–H aromatic), 1729
(C‚O thiazolidinone), 1681 (C‚O), 1543 (C‚C aromatic),
1441 (C–N benzothiazole), 849 (C–Cl), 693 (C–S–C thiazolid-
inone), 617 (C–S–C benzothiazole); 1H NMR (300 MHz,
DMSO-d6) d ppm: 11.77 (s, 1H, CONH), 8.05 (s, 1H, NH),
7.58–7.61 (m, 7H, Ar-H), 3.88 (s, 1H, OCH3), 2.55 (s, 2H,
CH2 thiazolidinone);
13C NMR (400 MHz, DMSO-d6) d
ppm: 174.5, 168.8, 158.3, 153.8, 151.3, 151.3, 132.3, 129.8,
128.1, 127.6, 125.8, 121.2, 120.9, 118.3, 116.5, 112.2, 57.9,
56.1, 35.2 (CH2 thiazolidinone); MS [EI] m/z 436 [M
++2],
435 [M++1], 434 [M+].
2.5.7. 1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(2-(4-nitrophenyl)-
4-oxothiazolidin-3-yl) urea (5g)
IR (KBr) kmax (cm
1): 3236 (NH), 3136 (C–H aromatic), 1737
(C‚O thiazolidinone), 1691 (C‚O), 1551 (C‚C aromatic),
1457 (C–N benzothiazole), 1369 (NO2), 854 (C–Cl), 688
(C–S–C thiazolidinone), 628 (C–S–C benzothiazole); 1H
NMR (300 MHz, DMSO-d6) d ppm: 11.71 (s, 1H, CONH),
8.08 (s, 1H, NH), 7.46–7.54 (m, 7H, Ar-H), 2.52 (s, 2H, CH2
thiazolidinone); 13C NMR (400 MHz, DMSO-d6) d ppm:
174.5, 168.8, 153.8, 151.3, 146.3, 145.3, 132.3, 129.8, 129.6,
125.8, 123.8, 121.2, 63.8, 35.2 (CH2 thiazolidinone); MS [EI]
m/z 451 [M++2], 450 [M++1], 449 [M+].
2.6. 1-(3-Chloro-2-oxo-4-substituted phenylazetidin-1-yl)-3-(6-
chlorobenzo[d]thiazol-2yl)urea (6a–g)
A solution of 4 (0.01 mol) in dioxane (20 mL) was added to a
well stirred mixture of chloroacetylchloride (0.012 mol) and
triethylamine (Et3N) (0.012 mol) in dioxane (10 mL) at
0–5 C. The reaction mixture was then stirred for 8 h, kept
for 2 days at room temperature and then treated with cold
water. The solid thus obtained was ﬁltered, washed with water
and recrystallised from methanol.
2.6.1. 1-(3-Chloro-2-oxo-4-phenylazetidin-1-yl)-3-(6-chloro
benzo[d]thiazol-2yl)urea (6a)
IR (KBr) kmax (cm
1): 3250 (NH), 1745 (C‚O b lactam ring),
1670 (C‚O), 1560 (C‚C), 1442 (C–N benzothiazole), 742 (C–
Cl), 638 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-
d6) d ppm: 10.41 (s, 1H, CONH), 7.70 (s, 1H, N–CH b lactam
ring), 6.61–6.69 (m,8H,Ar-H); 13C NMR (400 MHz, DMSO-
d6) d ppm: 174.5, 163.5 (b lactam ring), 153.8, 151.3, 143.5,
132.3, 129.8, 128.5, 126.9, 126.7, 125.8, 121.2, 118.3, 66.9,
63.7; MS [EI] m/z 410 [M++3], 408 [M++1], 407 [M+].
2.6.2. 1-(3-Chloro-2-(2-chlorophenyl)-4-oxoazetidin-1-yl)-3-
(6-chlorobenzo[d]thiazol-2yl)urea (6b)
IR (KBr) kmax (cm
1): 3244 (NH), 1752 (C‚O b lactam ring),
1673 (C‚O), 1566 (C‚C), 1447 (C–N benzothiazole), 742 (C–
Cl), 643 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-d6) d ppm: 10.44 (s, 1H, CONH), 7.72 (s, 1H, N–CH b lactam
ring), 6.64–6.69 (m, 8H, Ar-H); 13C NMR (400 MHz, DMSO-
d6) d ppm: 174.5, 163.5 (b lactam ring), 153.8, 151.3, 143.5,
132.3, 132.2, 129.8, 128.6, 128.3, 128.1, 126.6, 125.8, 121.2,
118.3, 63.2, 61.8; MS [EI] m/z 443 [M++3], 441 [M+], 439
[M+-2].
2.6.3. 1-(3-Chloro-2-(2,4-dichlorophenyl)-4-oxoazetidin-1-yl)-
3-(6-chlorobenzo[d]thiazol-2-yl)urea (6c)
IR (KBr) kmax (cm
1): 3253 (NH), 1758 (C‚O b lactam ring),
1677 (C‚O), 1568 (C‚C), 1456 (C–N benzothiazole), 751 (C–
Cl), 647 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-
d6) d ppm: 10.42 (s, 1H, CONH), 7.71 (s, 1H, N–CH b lactam
ring), 6.68–6.72 (m, 6H, Ar-H); 13C NMR (400 MHz, DMSO-
d6) d ppm: 174.5, 163.5 (b lactam ring), 153.8, 151.3, 151.1,
141.6, 133.7, 132.3, 131.1, 129.8, 126.7, 125.8, 121.2, 119.6,
118.3, 63.2, 61.8; MS [EI] m/z 477 [M++1], 475 [M+1],
473 [M+3].
2.6.4. 1-(3-Chloro-2-oxo-4-p-tolylazetidin-1-yl)-3-(6-chloro
benzo[d]thiazol-2-yl)urea (6d)
IR (KBr) kmax (cm
1): 3261 (NH), 1768 (C‚O b lactam ring),
1675 (C‚O), 1574 (C‚C), 1460 (C–N benzothiazole), 767 (C–
Cl), 651 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-
d6) d ppm: 10.46 (s, 1H, CONH), 7.75 (s, 1H, N–CH b lactam
ring), 6.58–6.62 (m,7H, Ar-H), 2.37 (s, 3H, CH3);
13C NMR
(400 MHz, DMSO-d6) d ppm: 174.5, 163.5 (b lactam ring),
153.8, 151.3, 140.5, 136.4, 132.3, 129.8, 128.8, 125.8, 125.3,
121.2, 118.3, 66.9, 63.7, 21.3; MS [EI] m/z 423 [M++2], 422
[M++1], 421 [M+].
2.6.5. 4-(3-Chloro-1-(3-(6-chlorobenzo[d]thiazol-2-yl)ureido)-
4-oxoazetidin-2-yl)phenyl acetate (6e)
IR (KBr) kmax (cm
1): 3259 (NH), 1772 (C‚O b lactam ring),
1681 (C‚O), 1577 (C‚C), 1454 (C–N benzothiazole), 771 (C–
Cl), 656 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-
d6) d ppm: 10.45 (s, 1H, CONH), 7.74 (s, 1H, N–CH b lactam
ring), 6.56–6.61 (m,7H,Ar-H), 2.61 (s,3H, OCOCH3);
13C
NMR (400 MHz, DMSO-d6) d ppm: 174.5, 163.5 (b lactam
ring), 169.0, 153.8, 149.3, 140.3, 132.3, 129.8, 126.0, 125.8,
121.4, 121.2, 66.9, 63.7, 20.3; MS [EI] m/z 466 [M++1], 465
[M+], 464 [M+1].
2.6.6. 1-(3-Chloro-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl)-3-
(6-chlorobenzo[d]thiazol-2-yl)urea (6f)
IR (KBr) kmax (cm
1): 3266 (NH), 1781 (C‚O b lactam ring),
1684 (C‚O), 1577 (C‚C), 1453 (C–N benzothiazole), 773 (C–
Cl), 658 (C–S–C benzothiazole); 1H NMR (300 MHz, DMSO-
d6) d ppm: 10.44 (s, 1H, CONH), 7.73 (s, 1H, N–CH b lactam
ring), 6.58–6.67 (m, 7H, Ar-H), 3.85 (s, 1H, OCH3);
13C NMR
(400 MHz, DMSO-d6) d ppm: 174.5, 163.5 (b lactam ring),
158.6, 153.8, 151.3, 135.8, 132.3, 129.8, 126.6, 125.8, 121.2,
118.3, 114.1, 66.9, 63.7, 55.8; MS [EI] m/z 438 [M++1], 437
[M+], 436 [M+1].
2.6.7. 1-(3-Chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl)-3-(6-
chlorobenzo[d]thiazol-2-yl)urea (6g)
IR (KBr) kmax (cm
1): 3264 (NH), 1784 (C‚O b lactam ring),
1676 (C‚O), 1580 (C‚C), 1457 (C–N benzothiazole), 1374
(NO2), 776 (C–Cl), 660 (C–S–C benzothiazole);
1H NMR
(300 MHz, DMSO-d6) d ppm: 10.43 (s, 1H, CONH), 7.75 (s,
1H, N–CH b lactam ring), 6.55–6.60 (m, 7H, Ar-H); 13C
Scheme 1 Synthetic route for the synthesis of title compounds.
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ring), 153.8, 151.3, 149.6, 145.9, 132.3, 129.8, 125.8, 123.7,
123.4, 121.2, 66.9, 63.7; MS [EI] m/z 453 [M++1], 452
[M+],451 [M+1].
2.7. Antimicrobial activity
All the synthesized compounds were tested for their in vitro anti-
microbial activity against the Gram positive bacteria Staphylo-
coccus aureus (ATCC-25923), the Gram-negative bacteria
Escherichia coli (ATCC-25922), Pseudomonas aeruginosa
(ATCC-27853) and Klebsiella pneumoniae (ATCC-700603) in
the nutrient agar media, and fungi Candida albicans (ATCC-
2091), Aspergillus niger (MTCC-281), Aspergillus ﬂavus
(MTCC-277),Monascus purpureus (MTCC369) andPenicillium
citrinum (NCIM-768) in Sabouraud dextrose medium at 200,
100, 50, 25 and 12.5 lg/mL concentrations by using serial plate
dilution method. The minimum inhibitory concentrations
(MIC’s) values were determined by comparison to oﬂoxacin
and ketoconazole as the reference drugs for bacterial and fungal
activity, respectively, as shown in Tables 2 and 3. Standard anti-
biotics oﬂoxacin and ketoconzole were used as reference drugs
at 50, 25 and 12.5 lg/mL concentrations. The minimum inhibi-
tory concentration (MIC) was deﬁned as the lowest concentra-
tion of the compounds that inhibited the visible growth of
microorganisms on the plate.3. Results and discussion
3.1. Chemistry
1-(6-Chlorobenzo[d]thiazol-2-yl)-3-(4-oxo-2-substituted phe-
nylthiazolidin-3-yl)urea (5a–g) and 1-(3-chloro-2-oxo-4-substi-
tuted phenylazetidin-1-yl)-3-(6-chlorobenzo[d]thiazol-2yl)urea
(6a–g) were prepared according to the procedure outlined in
Scheme 1. The required 2-substituted benzylidene-N-(6-chloro-
benzo[d]thiazol-2-yl)hydrazinecarboxamide (4a–g) was synthe-
sized by reacting N-(6-chlorobenzo[d]thiazol-2-yl)hydrazine
carboxamide (3) with substituted aromatic aldehyde in etha-
nol. This salt underwent ring closure by condensation with
thioglycollic acid to give the required title compounds (5a–
g). The synthesis of compounds (6a–g) was also accomplished
in a single step by reacting the 2-substituted benzylidene-N-(6-
chlorobenzo[d]thiazol-2-yl)hydrazinecarboxamide (4a–g) with
chloroacetyl chloride and triethylamine in the presence of
dioxane, respectively. The structure of the synthesized com-
pounds was conﬁrmed by elemental analysis and spectral data
(IR, 1H NMR, 13C NMR & Mass). Physicochemical data for
the 2-substituted benzylidene-N-(6-chlorobenzo[d]thiazol-2-
yl)hydrazinecarboxamide derivatives (4a–g, 5a–g, 6a–g) are gi-
ven in Table 1.
The IR spectra of compounds 4a–g showed absorption
peaks at 3318 and 1668 cm–1 due to N–H, C‚O and –N‚CH
stretching vibrations. The appearance of the stretching of the
C‚O of thiazolidinone and b-lactam ring at 1726 and
1745 cm–1, respectively, in the spectra of the derivatives, to-
gether with the C‚O stretching at 1664 and 1670 cm–1 con-
ﬁrmed the formation of the compounds 5a–g and 6a–g.
The 1H-NMR spectra of compounds 4a–g revealed a mul-
tiplet at d 7.77–7.81 ppm for the aromatic ring and singlets
at d 6.10 and 7.90 ppm for –NH and –N‚CH, respectively.The disappearance of the singlet peak of –N‚CH and the
presence of a singlet peak at d 2.48 and 7.70 of –CH2 of thia-
zolidinone and –N–CH of b-lactam ring proved that these
compounds participated in the cyclisation reaction and formed
the desired compounds.
This was further conﬁrmed by 13C–NMR spectrum of the
title compounds 5a–g and 6a–g which showed peaks at 35.2
and 163.5 ppm suggesting the presence of –CH2 and –C‚O
of thiazolidine and b-lactam ring, respectively.
The elemental analysis and molecular ion peaks of com-
pounds 5a–g and 6a–g were consistent with the assigned
structure.
3.2. Antimicrobial activity
The investigation of antibacterial and antifungal screening
data revealed that all the tested compounds 5a–g and 6a–g
showed good to moderate inhibition at 12.5–200 lg/mL in
DMSO. The compounds 5c, 5d, 5g, 6c and 6f showed compar-
atively good activity against all the bacterial strains. The good
activity is attributed to the presence of pharmacologically ac-
tive 2,4-dichloro (5c), methyl (5d), 4-nitro (5g) groups attached
to the phenyl group at position 2 of the thiazolidin-4-one ring,
whereas 2,4-dichlorophenyl (6c) and phenoxy group (6f) at-
tached at the fourth position of the b-lactam moiety. When
these groups were replaced by 2-chlorophenyl (5b, 6b) and
acetyl phenyl (5e, 6e), a sharp decrease in activity against most
of the strains was observed. Compounds 5a, 5f, 6a, 6d and 6g
exhibited moderate activity compared to that of standard
oﬂoxacin against all the bacterial strains. Further, the result
showed that Gram-negative exhibited better activity than
Gram positive organisms.
Compounds 5c, 5d, 5f, 6e and 6g showed comparatively
good activity against all the fungal strains. The structure of
these compounds contains biologically active 2,4-dichloro-
phenyl (5c), methylphenyl (5d) and phenoxy (5f) groups at-
tached at position 2 of the thiazolidin-4-one ring and acetyl
Table 1 Physical and analytical data of benzothiazole derivatives 4, 5 & 6a–g.
Compound R Mol. formula Yield (%) M.P. (C) Mol. weight Rf Analysis % found (calculated)
C H N
4a C15H11ClN4OS 84 153 330.79 0.8 54.46
(54.50)
3.35
(3.37)
16.94
(16.63)
4b C15H10Cl2N4OS 88 198 365.24 0.6 49.33
(49.38)
2.76
(2.71)
15.34
(15.39)
4c C15H9Cl3N4OS 80 136 399.68 0.7 45.08
(45.11)
2.27
(2.29)
14.02
(14.08)
4d C16H13ClN4OS 76 149 344.82 0.9 55.73
(55.67)
3.80
(3.76)
16.25
(16.28)
4e C17H13ClN4O3S 83 164 388.83 0.6 52.51
(52.54)
3.37
(3.39)
14.41
(14.44)
4f C16H13ClN4O2S 79 157 360.82 05 53.26
(53.29)
3.63
(3.57)
15.53
(15.50)
4g C15H10ClN5O3S 81 181 375.79 0.8 47.94
(47.78)
2.68
(2.62)
18.64
(18.67)
5a C17H13Cl N4O2S2 77 222 404.89 0.7 50.43
(50.46)
3.24
(3.28)
13.84
(13.66)
5b C17H12Cl2N4O2S2 79 238 439.34 0.6 46.47
(46.49)
2.75
(2.71)
12.75
(12.69)
5c C17H11Cl3N4O2S2 70 208 473.78 0.8 43.10
(43.14)
2.34
(2.37)
11.83
(11.76)
5d C18H15ClN4O2S2 66 258 418.92 0.7 51.61
(51.58)
3.61
(3.64)
13.37
(13.39)
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Table 1 (continued)
Compound R Mol. formula Yield (%) M.P. (C) Mol. weight Rf Analysis % found (calculated)
C H N
5e C19H15ClN4O4S2 71 214 462.93 0.9 49.30
(49.34)
3.27
(3.31)
12.10
(12.14)
5f C18H15ClN4O3S2 74 280 434.92 0.6 49.71
(49.67)
3.48
(3.50)
12.88
(12.74)
5g C17H12ClN5O4S2 80 202 449.89 0.8 46.40
(46.43)
3.46
(3.51)
15.03
(15.09)
6a C17H12Cl2N4O2S 71 226 407.27 0.7 50.13
(50.17)
2.97
(2.88)
13.76
(13.64)
6b C17H11Cl3N4O2S 78 232 441.72 0.9 46.22
(46.28)
2.51
(2.54)
12.68
(12.65)
6c C17H10Cl4N4O2S 73 262 476.16 0.5 42.88
(42.79)
2.12
(2.16)
11.77
(11.72)
6d C18H14Cl2N4O2S 76 217 421.30 0.7 51.32
(51.37)
3.35
(3.39)
13.30
(13.34)
6e C19H14Cl2N4O4S 77 238 465.31 0.9 49.04
(49.10)
3.03
(3.07)
12.04
(12.08)
6f C18H14Cl2N4O3S 72 219 437.30 0.8 49.44
(49.47)
3.23
(3.27)
12.81
(12.76)
6g C17H11Cl2N5O4S 75 210 452.27 0.6 45.15
(45.19)
2.45
(2.48)
15.48
(15.51)
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position of b-lactam ring, respectively. Compounds 5a, 5b,
5e, 5g, 6a, 6b and 6c showed moderate activity compared to
that of the standard against all the fungal strains. All the com-pounds showed good to moderate activity against all patho-
genic fungal strains except compounds 6d and 6f having
methyl and phenoxy groups attached at the fourth position
of the b-lactam nucleus.
Table 2 Antibacterial activity of the title compounds 5 & 6a–g.
Compounds Zone of inhibition in mm and MIC (minimum inhibitory concentration) in lg/mL
S. aureus E. coli P. aeruginosa K. pneumoniae
5a 13 (100) 17 (50) 19 (50) 19 (50)
5b 5 (<200) 8 (<200) 4 (<200) 8 (<200)
5c 22 (25) 25 (25) 29 (12.5) 27 (12.5)
5d 22 (25) 30 (12.5) 28 (12.5) 27 (12.5)
5e 3 (<200) 8 (<200) 6 (<200) 7 (<200)
5f 14 (100) 19 (50) 18 (50) 20 (50)
5g 27 (12.5) 30 (12.5) 27 (12.5) 30 (12.5)
6a 14 (100) 19 (50) 19 (50) 20 (50)
6b 8 (<200) 7 (<200) 9 (<200) 7 (<200)
6c 22 (25) 29 (12.5) 30 (12.5) 28 (12.5)
6d 12 (100) 17 (50) 19 (50) 18 (50)
6e 4 (<200) 9 (<200) 8 (<200) 7 (<200)
6f 24 (25) 27 (12.5) 29 (12.5) 30 (12.5)
6g 13 (100) 20 (50) 19 (50) 16 (50)
Oﬂoxacin 22 (25) 30 (12.5) 27 (12.5) 29 (12.5)
The ﬁgures in the table show the zone of inhibition (mm) and the corresponding MIC (lg/mL) values in brackets.
Table 3 Antifungal activity of the title compounds 5 & 6a–g.
Compound Zone of inhibition in mm and MIC (minimum inhibitory concentration) in lg/mL
C. albicans A. niger A. ﬂavus M. purpureus P. citrinum
5a 19 (50) 19 (50) 14 (100) 13 (100) 19 (50)
5b 18 (50) 11 (100) 14 (100) 20 (50) 17 (50)
5c 28 (12.5) 29 (12.5) 25 (25) 24 (25) 30 (12.5)
5d 29 (12.5) 28 (12.5) 27 (12.5) 21 (25) 23 (25)
5e 19 (50) 14 (100) 20 (50) 20 (50) 15 (50)
5f 22 (25) 24 (25) 29 (12.5) 25 (25) 29 (12.5)
5g 18 (50) 12 (100) 14 (100) 19 (50) 14 (100)
6a 16 (50) 19 (50) 18 (50) 13 (100) 19 (50)
6b 20 (50) 14 (100) 15 (100) 13 (100) 20 (50)
6c 20 (50) 15 (100) 13 (100) 18 (50) 19 (50)
6d 7 (<200) 8 (<200) 9 (<200) 6 (<200) 7 (<200)
6e 24 (25) 30 (12.5) 29 (12.5) 26 (12.5) 25 (25)
6f 8 (<200) 9 (<200) 8 (<200) 4 (<200) 7 (<200)
6g 30 (12.5) 27 (12.5) 30 (12.5) 22 (25) 29 (12.5)
Ketoconazole 30 (12.5) 28 (12.5) 25 (25) 30 (12.5) 24 (25)
The ﬁgures in the table show the zone of inhibition (mm) and the corresponding MIC (lg/mL) values in brackets.
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 The presence of 2,4-dichloro, methyl and 4-nitro groups
attached to the phenyl at position 2 of the thiazolidin-4-
ones ring and the presence of 2,4-dichloro and phenoxy
groups attached at fourth position of azetidin-2-ones moi-
ety showed good activity against all the bacterial strains.
 Replacing the above substituent with one chloro and acetyl
group results in a sharp decrease of antibacterial activity for
both thiazolidin-4-ones and azetidin-2-ones nucleus.
 Presence of 2,4-dichloro, methyl and phenoxy groups
attached at position 2 of the thiazolidin-4-ones ring and
presence of acetyl and nitro groups attached at the fourth
position of the b lactam moiety showed increase in activity
against all the fungal strains. Replacing the above substituent of the b lactam moiety with
methyl and phenoxy groups attached at fourth position
results in sharp decrease of antifungal activity.
 Further, b lactam derivatives are found to be more active
than thiazolidinone derivatives against all pathogenic bacte-
rial and fungal strains. The result also shows that gram-
negative exhibited better activity than gram positive
organisms.
 Thus, heterocycles accommodating either of the subunits
i.e. thiazolidine-4-ones or azetidin-2-ones are expected to
prove the therapeutic relevance and their utility in
medicinal chemistry and drug development. Ongoing
research focuses on the same molecular hybrid template
with the incorporation of more effective substituents
in search of new speciﬁc and effective antimicrobial
agents.
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